Ungeremine exhibits inhibitory effects on human leukemia cells in vitro and demonstrates antitumor activity in animal models; it acts as an effective anticancer agent by arresting the cell cycle at the G2 phase, reducing the percentage of G1-phase cells, increasing G2+M-phase cells, and significantly suppressing the mitotic index of cancer cells, particularly during early and mid-stages of cell division.